JPWO2020180624A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020180624A5
JPWO2020180624A5 JP2021545793A JP2021545793A JPWO2020180624A5 JP WO2020180624 A5 JPWO2020180624 A5 JP WO2020180624A5 JP 2021545793 A JP2021545793 A JP 2021545793A JP 2021545793 A JP2021545793 A JP 2021545793A JP WO2020180624 A5 JPWO2020180624 A5 JP WO2020180624A5
Authority
JP
Japan
Prior art keywords
lower alkyl
alkyl
halo
pharmaceutically acceptable
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021545793A
Other languages
English (en)
Japanese (ja)
Other versions
JP7503560B2 (ja
JP2022522334A5 (https=
JP2022522334A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/020199 external-priority patent/WO2020180624A1/en
Publication of JP2022522334A publication Critical patent/JP2022522334A/ja
Publication of JPWO2020180624A5 publication Critical patent/JPWO2020180624A5/ja
Publication of JP2022522334A5 publication Critical patent/JP2022522334A5/ja
Application granted granted Critical
Publication of JP7503560B2 publication Critical patent/JP7503560B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021545793A 2019-03-01 2020-02-27 新規な甲状腺模倣物 Active JP7503560B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962812890P 2019-03-01 2019-03-01
US62/812,890 2019-03-01
US201962953100P 2019-12-23 2019-12-23
US62/953,100 2019-12-23
PCT/US2020/020199 WO2020180624A1 (en) 2019-03-01 2020-02-27 Novel thyromimetics

Publications (4)

Publication Number Publication Date
JP2022522334A JP2022522334A (ja) 2022-04-18
JPWO2020180624A5 true JPWO2020180624A5 (https=) 2023-03-03
JP2022522334A5 JP2022522334A5 (https=) 2023-03-03
JP7503560B2 JP7503560B2 (ja) 2024-06-20

Family

ID=70005799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021545793A Active JP7503560B2 (ja) 2019-03-01 2020-02-27 新規な甲状腺模倣物

Country Status (7)

Country Link
US (1) US11667606B2 (https=)
EP (1) EP3931180A1 (https=)
JP (1) JP7503560B2 (https=)
CN (1) CN113784950A (https=)
AU (1) AU2020232205A1 (https=)
CA (1) CA3130371A1 (https=)
WO (1) WO2020180624A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3894383A1 (en) 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
KR20220121239A (ko) 2019-11-29 2022-08-31 아우토반 쎄라퓨틱스, 인크. 신규한 갑상선 호르몬 모방제
JP7813730B2 (ja) 2020-06-17 2026-02-13 オートバーン セラピューティクス,インク. 甲状腺様作用剤
WO2021257851A1 (en) 2020-06-17 2021-12-23 Autobahn Therapeutics, Inc. Thyromimetics
TW202317528A (zh) 2021-06-24 2023-05-01 美商富曼西公司 用於防治無脊椎有害生物的唑類化合物
WO2023177667A1 (en) * 2022-03-16 2023-09-21 Brii Biosciences, Inc. Thyroid hormone receptor agonists
WO2025019825A2 (en) * 2023-07-20 2025-01-23 Brii Biosciences, Inc. Substituted 2-(3,5-dichloro-4-(4-hydroxy-benzyl)phenoxy)acetamide derivatives

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4723027A (en) 1982-11-22 1988-02-02 E. I. Du Pont De Nemours And Company Preparation of optically active alpha-hydroxynitriles
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4741897A (en) 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
DE10199033I2 (de) 1992-04-22 2003-01-09 Ligand Parmaceuticals Inc Retinoid-x Rezeptor selektive Verbindungen
DE4320444A1 (de) 1993-06-21 1994-12-22 Agfa Gevaert Ag Farbfotografisches Aufzeichnungsmaterial
AU717743B2 (en) 1995-12-13 2000-03-30 Regents Of The University Of California, The Nuclear receptor ligands and ligand binding domains
CA2260992C (en) 1996-08-20 2004-03-09 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
DE69924846T2 (de) 1998-06-30 2006-04-27 The Regents Of The University Of California, Oakland Thyroidhormon-analoga und verfahren zu ihrer herstellung
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
JP2003500483A (ja) 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター ビアリール化合物
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
CZ20022771A3 (cs) 2000-02-17 2003-09-17 Bristol-Myers Squibb Company Ligandy thyreoidního receptoru odvozené od anilinu
DE10024939A1 (de) 2000-05-19 2001-11-29 Bayer Ag Neue Diphenylmethanderivate für Arzneimittel
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
EP1337524A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB Substituted quinolines as antitumor agents
US6777442B2 (en) * 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
US20040267015A1 (en) 2001-04-05 2004-12-30 Ajita Bhat Peptide deformylase inhibitors
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7247748B2 (en) 2002-03-27 2007-07-24 Smithkline Corporation Amide compounds and methods of using the same
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
US7321065B2 (en) 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2006012015A2 (en) 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
JP2008513461A (ja) 2004-09-15 2008-05-01 オードウェイ リサーチ インスティテュート 血管形成を促進する甲状腺ホルモンアナログ
WO2006128056A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
CN101180097A (zh) 2005-05-26 2008-05-14 症变治疗公司 新型含次膦酸的拟甲状腺素药
AU2006249347A1 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
GB0606212D0 (en) 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
GB0608724D0 (en) 2006-05-03 2006-06-14 Karobio Ab Novel Pharmaceutical Compositions
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
WO2008052354A1 (en) 2006-11-03 2008-05-08 University Of Saskatchewan Method of treating demyelination diseases
CN101547898B (zh) 2006-12-10 2014-09-24 于崇曦 β-内酰胺类抗生素的透皮给药系统
CN101657193A (zh) 2007-03-09 2010-02-24 切尔西治疗公司 用于治疗纤维肌痛的屈昔多巴及其药物组合物
FI20075245A0 (fi) 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
CA2970273C (en) 2007-07-11 2020-04-14 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
EP2242745A1 (de) 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US8475804B2 (en) 2009-02-20 2013-07-02 U.S. Army Medical Research And Material Command Compositions and methods for treatment of filovirus-mediated diseases
US20120245213A1 (en) 2009-10-01 2012-09-27 Bedrich Mosinger Human type i taste receptor subunit 3 modulators and methods of using same
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
WO2013006734A1 (en) 2011-07-05 2013-01-10 St. Jude Children's Research Hospital Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
WO2013056232A2 (en) 2011-10-13 2013-04-18 Case Western Reserve University Rxr agonists compounds and methods
WO2014078892A1 (en) 2012-11-21 2014-05-30 Indyk Daniel A device and a test assembly for testing the integrity of a low voltage electrical network
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
WO2015013187A1 (en) 2013-07-22 2015-01-29 Metabolic Solutions Development Co., Llc Ppar-sparing compounds for the treatment of metabolic diseases
US10258613B2 (en) 2014-02-05 2019-04-16 The Board Of Regents Of The University Of Oklahoma Compositions for treating retinal degeneration and methods of production and use thereof
US20170114019A1 (en) 2014-06-04 2017-04-27 Haro Pharmaceutical Inc. 18-20 member bi-polycyclic compounds
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
EP3259246B1 (en) 2015-02-20 2023-03-22 Oregon Health & Science University Derivatives of sobetirome
US10532983B2 (en) 2015-07-20 2020-01-14 Oregon Health & Science University Quinolone-3-diarylethers
CN109475121B (zh) 2016-05-18 2021-06-25 俄勒冈健康科学大学 苏比替罗衍生物
US11325886B2 (en) 2016-08-12 2022-05-10 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
WO2018208707A1 (en) 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
IL276592B2 (en) 2018-02-14 2023-11-01 Univ Oregon Health & Science History of Subtirum
WO2019168842A1 (en) 2018-03-02 2019-09-06 Oregon Health & Science University Amide prodrugs of small molecule nuclear receptor modulators
WO2020118564A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
EP3894383A1 (en) 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
KR20220121239A (ko) 2019-11-29 2022-08-31 아우토반 쎄라퓨틱스, 인크. 신규한 갑상선 호르몬 모방제

Similar Documents

Publication Publication Date Title
JP2024050527A5 (https=)
JPWO2020180624A5 (https=)
JP2020528889A5 (https=)
JP2021534106A5 (https=)
JP2020502047A5 (https=)
CN106232136A (zh) 用于治疗hbv感染的联合疗法
JP2018507886A5 (https=)
JPWO2023099623A5 (https=)
JP2020502092A5 (https=)
JP2009527462A5 (https=)
JP2019510082A5 (https=)
HRP20251468T1 (hr) Agonist dvostrukog receptora gip i glp-1, farmaceutski pripravak i upotreba
JP2017533237A5 (https=)
JP2024170457A5 (https=)
JP2019524814A5 (https=)
JPWO2021108549A5 (https=)
AR072611A1 (es) Compuestos de 3-(fenoxifenilmetil)pirrolidina, un metodo para su preparacion, intermediario de sintesis y su proceso de obtencion, composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de 5-ht y ne.
JP2021520415A5 (https=)
JP2016537432A5 (https=)
JPWO2020119819A5 (https=)
JP2021510168A5 (https=)
JPWO2023178099A5 (https=)
JPWO2021257851A5 (https=)
JPWO2020123861A5 (https=)
JPWO2021071821A5 (https=)